Migraines – headaches associated with nausea and sensitivity to light and sound – affect 12% of adults in the United States, according to the American Migraine Foundation. In workers’ comp, certain workplace injuries can exacerbate preexisting migraine conditions, and it has also been suggested that traumatic brain injury (TBI) may be a risk factor for migraines.
The prevalence of migraines, along with increasing awareness about novel drug treatments, are fueling rapid growth in the global migraine drug market. That market size was $6.7 billion in 2022 and is expected to reach $10.9 billion by 2032.
In 2019, the FDA approved several migraine treatments within a new class called calcitonin gene-related peptide (CGRP)-targeted agents. These medications are designed to target CGRP, a protein which causes intense inflammation in coverings of the brain when released. Since 2019, new CGRP inhibitors have continued to enter the market in various formulations, including oral solutions, nasal sprays, and disintegrating tablets. According to the above projections, the CGRP inhibitors market segment is anticipated to post the quickest revenue compound annual growth rate (CAGR) by 2030.
Continue reading this article in full on the Healthesystems blog.
